Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma ...Middle East

HADDONFIELD, N.J., Jan. 19, 2023 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced that the U.S. Food and Drug...

Hence then, the article about linnaeus therapeutics granted orphan drug designation for lns8801 for the treatment of patients with metastatic cutaneous melanoma was published today ( Thursday 19/01/2023 - 05:13 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma )

Also on site :

• Mercedes-Benz ‘willing’ to move into defense production – CEO
• Deadly virus outbreak kills 65 in DR Congo
• The Dietitian-Approved Starbucks Matcha Order You Need To Try